Cargando…

Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens

PURPOSE: Tusamitamab ravtansine is an antibody–drug conjugate that targets carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) and delivers a cytotoxic maytansinoid payload. In a phase I dose-escalation study, the maximum tolerated dose (MTD) was 100 mg/m(2) every 2 weeks (Q2W). Here...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tabernero, Josep, Bedard, Philippe L., Bang, Yung-Jue, Vieito, Maria, Ryu, Min-Hee, Fagniez, Nathalie, Chadjaa, Mustapha, Soufflet, Christine, Masson, Nina, Gazzah, Anas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10461573/ https://www.ncbi.nlm.nih.gov/pubmed/37645622 http://dx.doi.org/10.1158/2767-9764.CRC-23-0284

Ejemplares similares

Integrated multiple analytes and semi-mechanistic population pharmacokinetic model of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate
por: Pouzin, Clemence, et al.
Publicado: (2022)

Covariate analysis of tusamitamab ravtansine, a DM4 anti‐CEACAM5 antibody‐drug conjugate, based on first‐in‐human study
por: Pouzin, Clemence, et al.
Publicado: (2022)

Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies
por: Schönfeld, Kurt, et al.
Publicado: (2017)

Activity of Indatuximab Ravtansine against Triple-Negative Breast Cancer in Preclinical Tumor Models
por: Schönfeld, Kurt, et al.
Publicado: (2018)

Anetumab ravtansine inhibits tumor growth and shows additive effect in combination with targeted agents and chemotherapy in mesothelin-expressing human ovarian cancer models
por: Quanz, Maria, et al.
Publicado: (2018)

Praluzatamab Ravtansine, a CD166-Targeting Antibody–Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial
por: Boni, Valentina, et al.
Publicado: (2022)

First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody–Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors
por: Hassan, Raffit, et al.
Publicado: (2020)

Safety and activity of anti-mesothelin antibody–drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study
por: Santin, Alessandro D, et al.
Publicado: (2023)

Modeling Pharmacokinetic Profiles of Insulin Regimens to Enhance Understanding of Subcutaneous Insulin Regimens
por: Tham, Lai San, et al.
Publicado: (2017)

KEYNOTE-859: a Phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma
por: Tabernero, Josep, et al.
Publicado: (2021)

Improving antitumor efficacy via combinatorial regimens of oncolytic virotherapy
por: Zhang, Bin, et al.
Publicado: (2020)

Discrepancies of assessments in a RECIST 1.1 phase II clinical trial – association between adjudication rate and variability in images and tumors selection
por: Beaumont, Hubert, et al.
Publicado: (2018)

A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy
por: Trnĕný, Marek, et al.
Publicado: (2018)

Improved Antitumor Efficacy and Pharmacokinetics of Bufalin via PEGylated Liposomes
por: Yuan, Jiani, et al.
Publicado: (2017)

Population pharmacokinetics and optimization of the dosing regimen of digoxin in adult patients
por: Komatsu, Toshiaki, et al.
Publicado: (2015)

Evaluation of Amikacin Pharmacokinetics and Pharmacodynamics for Optimal Initial Dosing Regimen
por: Kato, Hideo, et al.
Publicado: (2017)

Assessment of Vancomycin Pharmacokinetics and Dose Regimen Optimisation in Preterm Neonates
por: Mulubwa, Mwila, et al.
Publicado: (2020)

Impact of Dose Delays and Alternative Dosing Regimens on Pertuzumab Pharmacokinetics
por: Liu, Stephanie N., et al.
Publicado: (2021)

Population Pharmacokinetics and Dosing Regimen Optimization of Latamoxef in Chinese Children
por: Wang, Yang, et al.
Publicado: (2022)

Enhanced antitumor effect of binimetinib in combination with capecitabine for biliary tract cancer patients with mutations in the RAS/RAF/MEK/ERK pathway: phase Ib study
por: Kim, Jin Won, et al.
Publicado: (2019)

Pharmacokinetics of Levornidazole Tablet in Healthy Chinese Subjects and Proposed Dosing Regimen Based on Pharmacokinetic/Pharmacodynamic Analysis
por: Wu, Hailan, et al.
Publicado: (2021)

Pharmacokinetic properties and antitumor efficacy of the 5-fluorouracil loaded PEG-hydrogel
por: Yi, Hee, et al.
Publicado: (2010)

Preparation, Pharmacokinetics, and Antitumor Potential of Miltefosine-Loaded Nanostructured Lipid Carriers
por: Yu, Guo, et al.
Publicado: (2021)

Self-fused concatenation of interferon with enhanced bioactivity, pharmacokinetics and antitumor efficacy
por: Hu, Jin, et al.
Publicado: (2022)

Subcutaneous pharmacokinetics and dosage regimen of cefotaxime in buffalo calves (Bubalus bubalis)
por: Sharma, Suresh Kumar, et al.
Publicado: (2006)

Pharmacokinetic/pharmacodynamic modeling for the determination of a cimicoxib dosing regimen in the dog
por: Jeunesse, Elisabeth C, et al.
Publicado: (2013)

Dosing Regimen of Enrofloxacin Impacts Intestinal Pharmacokinetics and the Fecal Microbiota in Steers
por: Ferguson, Kaitlyn M., et al.
Publicado: (2018)

A Two-Dose Oritavancin Regimen Using Pharmacokinetic Estimation Analysis
por: Rose, Warren E., et al.
Publicado: (2020)

Population Pharmacokinetics Analysis of Amikacin Initial Dosing Regimen in Elderly Patients
por: Kato, Hideo, et al.
Publicado: (2021)

Effect of Synchronous Versus Sequential Regimens on the Pharmacokinetics and Biodistribution of Regorafenib with Irradiation
por: Tsai, Tung-Hu, et al.
Publicado: (2021)

Effects of danofloxacin dosing regimen on gastrointestinal pharmacokinetics and fecal microbiome in steers
por: Halleran, J. L., et al.
Publicado: (2021)

Population Pharmacokinetics and Dosing Regimen of Lithium in Chinese Patients With Bipolar Disorder
por: Jin, Zi-bin, et al.
Publicado: (2022)

Population Pharmacokinetic Modeling of Zaltoprofen in Healthy Adults: Exploring the Dosage Regimen
por: Jang, Ji-Hun, et al.
Publicado: (2023)

Impact of antitumor regimens on the outcomes of cancer patients with COVID-19: a pooled analysis
por: LU, Haohua, et al.
Publicado: (2021)

Alocasia cucullata Exhibits Strong Antitumor Effect In Vivo by Activating Antitumor Immunity
por: Peng, Qiuxian, et al.
Publicado: (2013)

Book Review: Debating Cancer: The Paradox in Cancer Research
por: Bang, Yung-Jue
Publicado: (2016)

Phase I Pharmacokinetic Study of Nivolumab in Korean Patients with Advanced Solid Tumors
por: Lee, Keun‐Wook, et al.
Publicado: (2017)

Preparation, Pharmacokinetics, and Antitumor Potential of Miltefosine-Loaded Nanostructured Lipid Carriers [Retraction]
Publicado: (2023)

Pharmacokinetics of Curcumin Delivered by Nanoparticles and the Relationship with Antitumor Efficacy: A Systematic Review
por: Silvestre, Fernanda, et al.
Publicado: (2023)

Clinical Use of Rivaroxaban: Pharmacokinetic and Pharmacodynamic Rationale for Dosing Regimens in Different Indications
por: Trujillo, Toby, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_m2hbmb6voum3911rsjri2uon48